Literature DB >> 10682664

Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancer.

B A Usmani1, M Janeczko, R Shen, M Mazumdar, C N Papandreou, D M Nanus.   

Abstract

The angiotensin I-converting enzyme (ACE) contains an insertion/deletion (I/D) polymorphism, with the DD genotype associated with benign renal diseases. The distribution frequencies of the D and I alleles, and the DD, DI and II genotypes were determined in DNA extracted from kidney tissues of 58 renal cancer patients. The observed frequencies in patients who develop renal cancer was not significantly different than the normal population.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10682664      PMCID： PMC2363311          DOI： 10.1054/bjoc.1999.0962

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  19 in total

1.  Infrequent ras oncogene point mutations in renal cell carcinoma.

Authors:  D M Nanus; I R Mentle; R J Motzer; N H Bander; A P Albino
Journal:  J Urol       Date:  1990-01       Impact factor: 7.450

2.  Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival.

Authors:  D M Nanus; B J Schmitz-Dräger; R J Motzer; A C Lee; V Vlamis; C Cordon-Cardo; A P Albino; V E Reuter
Journal:  J Natl Cancer Inst       Date:  1993-10-06       Impact factor: 13.506

3.  Mistyping ACE heterozygotes.

Authors:  V Shanmugam; K W Sell; B K Saha
Journal:  PCR Methods Appl       Date:  1993-10

4.  Induction of growth factor RNA expression in human malignant melanoma: markers of transformation.

Authors:  A P Albino; B M Davis; D M Nanus
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

5.  Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

Authors:  A F Lever; D J Hole; C R Gillis; I R McCallum; G T McInnes; P L MacKinnon; P A Meredith; L S Murray; J L Reid; J W Robertson
Journal:  Lancet       Date:  1998-07-18       Impact factor: 79.321

6.  Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A.

Authors:  D M Nanus; D Engelstein; G A Gastl; L Gluck; M J Vidal; M Morrison; C L Finstad; N H Bander; A P Albino
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

7.  Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications.

Authors:  M Marre; P Bernadet; Y Gallois; F Savagner; T T Guyene; M Hallab; F Cambien; P Passa; F Alhenc-Gelas
Journal:  Diabetes       Date:  1994-03       Impact factor: 9.461

8.  PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1).

Authors:  B Rigat; C Hubert; P Corvol; F Soubrier
Journal:  Nucleic Acids Res       Date:  1992-03-25       Impact factor: 16.971

9.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.

Authors:  B Rigat; C Hubert; F Alhenc-Gelas; F Cambien; P Corvol; F Soubrier
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

Review 10.  Angiotensin II as a renal growth factor.

Authors:  G Wolf; E G Neilson
Journal:  J Am Soc Nephrol       Date:  1993-03       Impact factor: 10.121
View more
  3 in total

Review 1.  Association between angiotensin I-converting enzyme gene polymorphism and susceptibility to cancer: a meta analysis.

Authors:  Kan Zhang; Dan Cheng; Lingling Yi; Huimin Shi; Guohua Zhen
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

2.  Associations of the Insertion/Deletion Polymorphism in the ACE Gene and Risk of Gastric Cancer: A Meta-Analysis.

Authors:  Noel Pabalan; Hamdi Jarjanazi; Hilmi Ozcelik
Journal:  J Gastrointest Cancer       Date:  2015-12

3.  Renin angiotensin system deregulation as renal cancer risk factor.

Authors:  Paweł Sobczuk; Cezary Szczylik; Camillo Porta; Anna M Czarnecka
Journal:  Oncol Lett       Date:  2017-08-25       Impact factor: 2.967
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.